Signalife Announces Anticipated Date of Transition to OTCBB
Monday September 8, 10:09 am ET
LOS ANGELES, Sept. 8 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) announced that it has filed its Form 25 with the Securities and Exchange Commission effecting the withdrawal of trading of its common stock on the American Stock Exchange ("AMEX"). The last day that Signalife's common stock will trade on AMEX will be Friday, September 12, 2008. Signalife expects that the company's common stock will be available for quotation on both the Over-The-Counter Bulletin Board and the Pink Sheets commencing upon the opening of market on Monday, September 15, 2008. Pursuant to OTCBB policy, it will assign a new trading symbol for Signalife's common stock following the close of trading on AMEX on Friday, September 12, 2008. Signalife will publicly announce the new trading symbol promptly upon receipt from the OTCBB.
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease. More information is located at www.signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause the companies' actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, the failure of Signalife's market maker to complete or timely complete the process of qualifying the shares for quotation on the OTCBB, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating the companies' technology and procure market acceptance for these products, failure to obtain federal or state or governmental or international regulatory approvals governing heart monitoring and other biomedical devices incorporating the technology, failure to obtain import and export capabilities in the various countries containing buyers and resellers and hospitals and clinics and doctors for the devices, inability to obtain physician, patient or insurance acceptance of or for heart monitoring and other biomedical incorporating of the technologies, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical and information solutions incorporating the companies' technologies. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Source: Signalife, Inc.
TechKim
